News

The fish oil-derived therapy is already approved in the US for patients with severe hypertriglyceridaemia.

The system gives users “greater flexibility” to customise the company’s established CRM.

The drug only managed to reach an efficacy of 7.4% in ‘peak season’ and 9.8% in the whole season, falling short of the expected 20%.

Galapagos and Gilead initially entered into a global collaboration for the development and commercialisation of the drug in inflammatory indications in 2015.

The drug was cleared for small cell lung cancer back in March.

Also earlier this year, analysis from Cancer Research UK found that excess weight causes more cases of certain cancers than smoking.

The company is set to conduct the first-in-human clinical trial of the novel cell therapy, TX200.

And the discovery could be “just the tip of the iceberg”.

More good news for the MSD, AstraZeneca drug.

The bottle is connected to an app which knows the dosage and regimen the patient requires.

The anti-TNF drug works by targeting a protein in the body called TNF-alpha.

The report recommends biomedical scientists avoid general search engines and vendor catalogue information and instead use two kinds of online resource.

The drug works by targeting the interleukin-6 receptor, a potential key driver of neuromyelitis optica spectrum disorder.

The PARP inhibitor is now the first and only of its kind in the UK to be approved in all lines of maintenance treatment.

The project puts an emphasis on the integrity and security of patient data, an important topic at the moment.